Clinical Trials Using Sapanisertib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Sapanisertib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-12 of 12
  • Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

    This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
    Location: 1189 locations

  • Sapanisertib in Treating Patients with Locally Advanced or Metastatic Bladder Cancer with TSC1 and / or TSC2 Mutations

    This pilot phase II trial studies how well sapanisertib works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic) with tuberous sclerosis (TSC)1 and / or TSC2 mutations (changes in deoxyribonucleic acid [DNA]). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 20 locations

  • Sapanisertib in Treating Patients with Metastatic Kidney Cancer Who Have Had Prior Treatment

    This phase II trial studies sapanisertib and how well it works in treating patients with kidney cancer that has spread to other places in the body (metastatic) and who have undergone prior treatment. Mechanistic target of rapamycin (mTOR) blockers, such as sapanisertib, are a newer type of cancer growth blocker that may stop the growth of metastatic kidney cancer.
    Location: 12 locations

  • Sapanisertib in Treating Patients with Stage IV or Recurrent Lung Cancer

    This phase II trial studies how well sapanisertib works in treating patients with lung cancer that is stage IV or has come back (recurrent) and has a mutation in the NFE2L2, KEAP-1, or KRAS gene. Damage to these genes may cause the cancer to grow. Sapanisertib may stop this from happening by blocking enzymes.
    Location: 7 locations

  • Sapanisertib and Osimertinib in Treating Patients with Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer after Progression on a Previous EGFR Tyrosine Kinase Inhibitor

    This phase I trial studies the side effects and best dose of sapanisertib when given together with osimertinib in treating patients with stage IV EGFR mutation positive non-small cell lung cancer that has progressed after treatment with an EGFR tyrosine kinase inhibitor. Sapanisertib and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Sapanisertib in Treating Patients with Newly Diagnosed or Refractory / Metastatic Anaplastic Thyroid Cancer

    This phase I / II trial studies the side effects and best dose of sapanisertib and to see how well it works in treating patients with anaplastic thyroid cancer that is newly diagnosed or has not responded to previous treatment (refractory) and has spread to other places in the body (metastatic). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Sapanisertib, Carboplatin, and Paclitaxel in Treating Participants with Recurrent or Refractory Malignant Solid Tumors

    This phase I trial studies the sides effects and best dose of sapanisertib, carboplatin, and paclitaxel in treating participants with malignant solid tumors that have come back or do not respond to treatment. Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing cells, by stopping them from dividing, or by stopping them from spreading. Giving sapanisertib, carboplatin, and paclitaxel may work better in treating participants with malignant solid tumors.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Sapanisertib and Metformin in Treating Patients with Advanced or Metastatic Relapsed or Refractory Cancers

    This phase I trial studies the side effects and best dose of sapanisertib and metformin in treating patients with cancers that have spread to other parts of the body (advanced / metastatic), have come back (recurrent), or do not respond to treatment (refractory). Sapanisertib and metformin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Sapanisertib and Alisertib in Treating Patients with Incurable Refractory Solid Tumors or Metastatic Triple-Negative Breast Cancer

    This phase Ib trial studies the side effects and best dose of sapanisertib and alisertib in treating patients with solid tumors that have no treatment currently available and do not respond to treatment or triple-negative breast cancer (TNBC) that has spread to other parts of the body. Sapanisertib and alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: University of Colorado Hospital, Aurora, Colorado

  • Sapanisertib and Letrozole in Treating Patients with Estrogen Receptor Positive and HER2 Negative Stage I-IV Breast Cancer

    This phase Ib trial studies the side effects of sapanisertib and letrozole in treating patients with estrogen receptor positive and HER2 negative stage I-IV breast cancer. Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as letrozole, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sapanisertib and letrozole before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

  • Sapanisertib and Ziv-Aflibercept in Treating Patients with Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

    This phase I trial studies the side effects and best dose of sapanisertib and ziv-aflibercept in treating patients with solid tumors that have come back (recurrent) and have spread to another place in the body (metastatic) or cannot be removed by surgery (unresectable). Sapanisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ziv-aflibercept may stop the growth of solid tumors by blocking the growth of new blood vessels necessary for tumor growth. Giving sapanisertib with ziv-aflibercept may kill more tumor cells.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Sapanisertib in Treating Patients with Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

    This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other places in the body, does not respond to treatment, or cannot be surgically removed. Drugs such as sapanisertib may stop the growth or shrink tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 396 locations